Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 315

1.

Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors.

Pros E, Saigi M, Alameda D, Gomez-Mariano G, Martinez-Delgado B, Alburquerque-Bejar JJ, Carretero J, Tonda R, Esteve-Codina A, Catala I, Palmero R, Jove M, Lazaro C, Patiño-Garcia A, Gil-Bazo I, Verdura S, Teulé A, Torres-Lanzas J, Sidransky D, Reguart N, Pio R, Juan-Vidal O, Nadal E, Felip E, Montuenga LM, Sanchez-Cespedes M.

Ann Oncol. 2020 Feb;31(2):274-282. doi: 10.1016/j.annonc.2019.09.001.

PMID:
31959344
2.

Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study.

Tan DS, Leighl NB, Riely GJ, Yang JC, Sequist LV, Wolf J, Seto T, Felip E, Aix SP, Jonnaert M, Pan C, Tan EY, Ko J, Moody SE, Kim DW.

Lancet Respir Med. 2020 Jan 15. pii: S2213-2600(19)30267-X. doi: 10.1016/S2213-2600(19)30267-X. [Epub ahead of print]

PMID:
31954624
3.

Serum concentrations of perfluorinated alkyl substances in farmers living in areas affected by water contamination in the Veneto Region (Northern Italy).

Ingelido AM, Abballe A, Gemma S, Dellatte E, Iacovella N, De Angelis G, Marra V, Russo F, Vazzoler M, Testai E, De Felip E.

Environ Int. 2020 Jan 11;136:105435. doi: 10.1016/j.envint.2019.105435. [Epub ahead of print]

4.

Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients.

Cedrés S, Ponce-Aix S, Iranzo P, Callejo A, Pardo N, Navarro A, Martinez-Marti A, Gómez-Abecia S, Zucchiatti AC, Sansano I, Enguita AB, Miquel JM, Viaplana C, Dienstmann R, Paz-Ares L, Felip E.

Clin Transl Oncol. 2020 Jan 8. doi: 10.1007/s12094-019-02275-9. [Epub ahead of print]

PMID:
31916017
5.

Epidermal growth factor receptor first generation tyrosine-kinase inhibitors.

Martinez-Marti A, Navarro A, Felip E.

Transl Lung Cancer Res. 2019 Nov;8(Suppl 3):S235-S246. doi: 10.21037/tlcr.2019.04.20. Review.

6.

Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial.

Molina-Vila MA, Stahel RA, Dafni U, Jordana-Ariza N, Balada-Bel A, Garzón-Ibáñez M, García-Peláez B, Mayo-de-Las-Casas C, Felip E, Fontecedro AC, Gautschi O, Peters S, Massutí B, Palmero R, Aix SP, Carcereny E, Früh M, Pless M, Popat S, Cuffe S, Bidoli P, Kammler R, Roschitzki-Voser H, Tsourti Z, Karachaliou N, Rosell R; results from the European Thoracic Oncology Platform (ETOP) BELIEF trial.

J Thorac Oncol. 2019 Dec 5. pii: S1556-0864(19)33715-3. doi: 10.1016/j.jtho.2019.11.023. [Epub ahead of print]

PMID:
31812754
7.

Erratum to "Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts" [Radiother. Oncol. 135 (2019) 74-77].

Putora PM, Glatzer M, De Ruysscher D, Faivre-Finn C, Belderbos J, Besse B, Blackhall F, Califano R, Cappuzzo F, de Marinis F, Dziadiuszko R, Felip E, Früh M, Garrido P, Le Pechoux C, McDonald F, Nestle U, Novello S, O' Brien M, Paz Ares L, Peeters S, Pöttgen C, Ramella S, Reck M, Troost EGC, Van Houtte P, Westeel V, Widder J, Mornex F, Slotman BJ.

Radiother Oncol. 2019 Dec;141:332. doi: 10.1016/j.radonc.2019.10.006. No abstract available.

PMID:
31810511
8.

Biomonitoring of the adult population in the area of turin waste incinerator: Baseline levels of polycyclic aromatic hydrocarbon metabolites.

Iamiceli AL, Abate V, Abballe A, Bena A, De Filippis SP, De Luca S, Fulgenzi AR, Iacovella N, Ingelido AM, Marra V, Miniero R, Farina E, Gandini M, Orengia M, De Felip E.

Environ Res. 2019 Nov 11:108903. doi: 10.1016/j.envres.2019.108903. [Epub ahead of print]

PMID:
31806290
9.

Final Overall Survival, Other Efficacy and Safety Results from ASCEND-3: Phase II Study of Ceritinib in ALKi-Naïve Patients With ALK-Rearranged Non-Small-Cell Lung Cancer.

Nishio M, Felip E, Orlov S, Park K, Yu CJ, Tsai CM, Cobo M, McKeage M, Su WC, Mok T, Scagliotti GV, Spigel DR, Viraswami-Appanna K, Chen Z, Passos VQ, Shaw AT.

J Thorac Oncol. 2019 Nov 25. pii: S1556-0864(19)33660-3. doi: 10.1016/j.jtho.2019.11.006. [Epub ahead of print]

10.

Capturing Hyperprogressive disease with immune checkpoint inhibitors using RECIST 1.1 criteria.

Matos I, Martin-Liberal J, Garcia-Ruiz A, Hierro C, Ochoa de Olza M, Viaplana C, Azaro A, Vieito M, Brana I, Mur G, Ros J, Mateos J, Villacampa G, Berché R, Oliveira M, Alsina M, Élez E, Oaknin A, Muñoz-Couselo E, Carles J, Felip E, Rodon J, Tabernero J, Dienstmann R, Perez-Lopez R, Garralda E.

Clin Cancer Res. 2019 Nov 22. pii: clincanres.2226.2019. doi: 10.1158/1078-0432.CCR-19-2226. [Epub ahead of print]

PMID:
31757877
11.

Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study.

Felip E, de Braud FG, Maur M, Loong HH, Shaw AT, Vansteenkiste JF, John T, Liu G, Lolkema MP, Selvaggi G, Giannone V, Cazorla P, Baum J, Balbin OA, Wang LV, Lau YY, Scott JW, Tan DS.

J Thorac Oncol. 2019 Oct 18. pii: S1556-0864(19)33564-6. doi: 10.1016/j.jtho.2019.10.006. [Epub ahead of print]

12.

Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

Garrido P, Conde E, de Castro J, Gómez-Román JJ, Felip E, Pijuan L, Isla D, Sanz J, Paz-Ares L, López-Ríos F.

Clin Transl Oncol. 2019 Oct 9. doi: 10.1007/s12094-019-02218-4. [Epub ahead of print]

PMID:
31598903
13.

Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer.

Gerber DE, Infante JR, Gordon MS, Goldberg SB, Martín M, Felip E, Martinez Garcia M, Schiller JH, Spigel DR, Cordova J, Westcott V, Wang Y, Shames DS, Choi Y, Kahn R, Dere RC, Samineni D, Xu J, Lin K, Wood K, Royer-Joo S, Lemahieu V, Schuth E, Vaze A, Maslyar D, Humke EW, Burris HA 3rd.

Clin Cancer Res. 2020 Jan 15;26(2):364-372. doi: 10.1158/1078-0432.CCR-18-3965. Epub 2019 Sep 20.

PMID:
31540980
14.

Real-world data on T-DM1 efficacy - results of a single-center retrospective study of HER2-positive breast cancer patients.

Hardy-Werbin M, Quiroga V, Cirauqui B, Romeo M, Felip E, Teruel I, Garcia JJ, Erasun C, España S, Cucurull M, Montprade E, Pardo JC, Carballo D, Velarde JM, Margeli M.

Sci Rep. 2019 Sep 4;9(1):12760. doi: 10.1038/s41598-019-49251-5.

15.

Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.

Nosaki K, Saka H, Hosomi Y, Baas P, de Castro G Jr, Reck M, Wu YL, Brahmer JR, Felip E, Sawada T, Noguchi K, Han SR, Piperdi B, Kush DA, Lopes G.

Lung Cancer. 2019 Sep;135:188-195. doi: 10.1016/j.lungcan.2019.07.004. Epub 2019 Jul 8.

PMID:
31446994
16.

An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer.

Morgensztern D, Karaseva N, Felip E, Delgado I, Burdaeva O, Dómine M, Lara P, Paik PK, Lassen U, Orlov S, Trigo J, Shomova M, Baker-Neblett K, Vasquez J, Wang X, Yan L, Mitrica I, DeYoung MP, Garrido P.

Lung Cancer. 2019 Oct;136:74-79. doi: 10.1016/j.lungcan.2019.08.011. Epub 2019 Aug 14.

PMID:
31446228
17.

A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer.

Cejalvo JM, Jacob W, Fleitas Kanonnikoff T, Felip E, Navarro Mendivil A, Martinez Garcia M, Taus Garcia A, Leighl N, Lassen U, Mau-Soerensen M, Adessi C, Michielin F, James I, Ceppi M, Hasmann M, Weisser M, Cervantes A.

ESMO Open. 2019 Jul 22;4(4):e000532. doi: 10.1136/esmoopen-2019-000532. eCollection 2019.

18.

Long duration of immunotherapy in a STK11 mutated/KRAS wild-type non-small cell lung cancer patient.

Domingues I, Cedres S, Callejo A, Vivancos A, Martinez-Marti A, Felip E.

Pulmonology. 2020 Jan - Feb;26(1):49-50. doi: 10.1016/j.pulmoe.2019.05.002. Epub 2019 Aug 7. No abstract available.

19.

Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus.

Isla D, de Castro J, García-Campelo R, Lianes P, Felip E, Garrido P, Paz-Ares L, Trigo JM.

Clin Transl Oncol. 2019 Jul 31. doi: 10.1007/s12094-019-02191-y. [Epub ahead of print]

PMID:
31368078
20.

Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study.

Conde E, Hernandez S, Martinez R, Angulo B, De Castro J, Collazo-Lorduy A, Jimenez B, Muriel A, Mate JL, Moran T, Aranda I, Massuti B, Rojo F, Domine M, Sansano I, Garcia F, Felip E, Mancheño N, Juan O, Sanz J, Gonzalez-Larriba JL, Atienza-Cuevas L, Arriola-Arellano E, Abdulkader I, Garcia-Gonzalez J, Camacho C, Rodriguez-Abreu D, Teixido C, Reguart N, Gonzalez-Piñeiro A, Lazaro-Quintela M, Lozano MD, Gurpide A, Gomez-Roman J, Lopez-Brea M, Pijuan L, Salido M, Arriola E, Company A, Insa A, Esteban-Rodriguez I, Saiz M, Azkona E, Alvarez R, Artal A, Plaza ML, Aguiar D, Enguita AB, Benito A, Paz-Ares L, Garrido P, Lopez-Rios F.

J Thorac Oncol. 2019 Dec;14(12):2120-2132. doi: 10.1016/j.jtho.2019.07.005. Epub 2019 Jul 23.

21.

Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.

Zugazagoitia J, Gómez-Rueda A, Jantus-Lewintre E, Isla D, Camps C, Ramos I, Trigo JM, Bernabé R, Juan-Vidal O, Sanchez-Torres JM, García-Campelo R, Provencio M, Felip E, de Castro J, Faull I, Lanman RB, Ponce-Aix S, Paz-Ares L, Garrido P.

Lung Cancer. 2019 Aug;134:72-78. doi: 10.1016/j.lungcan.2019.05.032. Epub 2019 May 30.

PMID:
31319999
22.

[Influence of systematic antibiotic prophylaxis and/or cystoscope cleaning/disinfecting method on urinary culture becoming positive after outpatient flexible cystoscopy.]

Martínez Rodríguez R, Felip E, Arzoz Fabregas M, Ruiz Domínguez J, Ibarz Servio L.

Arch Esp Urol. 2019 Jul;72(6):554-559. Spanish.

PMID:
31274119
23.

Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.

Peters S, Felip E, Dafni U, Belka C, Guckenberger M, Irigoyen A, Nadal E, Becker A, Vees H, Pless M, Martinez-Marti A, Tufman A, Lambrecht M, Andratschke N, Piguet AC, Kassapian M, Roschitzki-Voser H, Rabaglio-Poretti M, Stahel RA, Vansteenkiste J, De Ruysscher D.

Lung Cancer. 2019 Jul;133:83-87. doi: 10.1016/j.lungcan.2019.05.001. Epub 2019 May 3.

PMID:
31200833
24.

YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib.

Garmendia I, Pajares MJ, Hermida-Prado F, Ajona D, Bértolo C, Sainz C, Lavín A, Remírez AB, Valencia K, Moreno H, Ferrer I, Behrens C, Cuadrado M, Paz-Ares L, Bustelo XR, Gil-Bazo I, Alameda D, Lecanda F, Calvo A, Felip E, Sánchez-Céspedes M, Wistuba II, Granda-Diaz R, Rodrigo JP, García-Pedrero JM, Pio R, Montuenga LM, Agorreta J.

Am J Respir Crit Care Med. 2019 Oct 1;200(7):888-899. doi: 10.1164/rccm.201807-1292OC.

PMID:
31166114
25.

Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study.

Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, Patnaik A, Gubens M, Ramalingam SS, Felip E, Goldman JW, Scalzo C, Jensen E, Kush DA, Hui R.

J Clin Oncol. 2019 Oct 1;37(28):2518-2527. doi: 10.1200/JCO.19.00934. Epub 2019 Jun 2.

26.

Dual effect of the broad spectrum kinase inhibitor midostaurin in acute and latent HIV-1 infection.

Garcia-Vidal E, Badia R, Pujantell M, Castellví M, Felip E, Clotet B, Riveira-Muñoz E, Ballana E, Esté JA.

Antiviral Res. 2019 Aug;168:18-27. doi: 10.1016/j.antiviral.2019.05.003. Epub 2019 May 8.

PMID:
31077767
27.

Correction: Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer.

Morán T, Felip E, Bosch-Barrera J, de Aguirre I, Ramirez JL, Mesia C, Carcereny E, Roa D, Sais E, García Y, Blanco R, Sanchez S, Villacorta CR, Queralt C, Velarde JM, Rosell R.

Oncotarget. 2019 Apr 2;10(26):2576. doi: 10.18632/oncotarget.26855. eCollection 2019 Apr 2.

28.

Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts.

Putora PM, Glatzer M, De Ruysscher D, Faivre-Finn C, Belderbos J, Besse B, Blackhall F, Califano R, Cappuzzo F, de Marinis F, Dziadiuszko R, Felip E, Früh M, Garrido P, Le Pechoux C, McDonald F, Nestle U, Novello S, Brien MO, Paz Ares L, Peeters S, Pöttgen C, Ramella S, Reck M, Troost EGC, Van Houtte P, Westeel V, Widder J, Mornex F, Slotman BJ.

Radiother Oncol. 2019 Jun;135:74-77. doi: 10.1016/j.radonc.2019.02.010. Epub 2019 Mar 15. Erratum in: Radiother Oncol. 2019 Dec;141:332.

PMID:
31015173
29.

Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.

Michels S, Massutí B, Schildhaus HU, Franklin J, Sebastian M, Felip E, Grohé C, Rodriguez-Abreu D, Abdulla DSY, Bischoff H, Brandts C, Carcereny E, Corral J, Dingemans AC, Pereira E, Fassunke J, Fischer RN, Gardizi M, Heukamp L, Insa A, Kron A, Menon R, Persigehl T, Reck M, Riedel R, Rothschild SI, Scheel AH, Scheffler M, Schmalz P, Smit EF, Limburg M, Provencio M, Karachaliou N, Merkelbach-Bruse S, Hellmich M, Nogova L, Büttner R, Rosell R, Wolf J.

J Thorac Oncol. 2019 Jul;14(7):1266-1276. doi: 10.1016/j.jtho.2019.03.020. Epub 2019 Apr 9.

PMID:
30978502
30.

Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.

Sequist LV, Gray JE, Harb WA, Lopez-Chavez A, Doebele RC, Modiano MR, Jackman DM, Baggstrom MQ, Atmaca A, Felip E, Provencio M, Cobo M, Adiwijaya B, Kuesters G, Kamoun WS, Andreas K, Pipas JM, Santillana S, Cho BC, Park K, Shepherd FA.

Oncologist. 2019 Aug;24(8):1095-1102. doi: 10.1634/theoncologist.2018-0695. Epub 2019 Apr 11.

31.

Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts.

Putora PM, Glatzer M, Belderbos J, Besse B, Blackhall F, Califano R, Cappuzzo F, de Marinis F, Dziadziuszko R, Felip E, Faivre-Finn C, Früh M, Garrido P, Le Pechoux C, McDonald F, Nestle U, Novello S, O'Brien M, Paz Ares L, Peeters S, Pöttgen C, Ramella S, Reck M, Slotman B, Troost EGC, Van Houtte P, Westeel V, Widder J, Mornex F, De Ruysscher D.

Radiother Oncol. 2019 Apr;133:163-166. doi: 10.1016/j.radonc.2018.12.014. Epub 2019 Jan 31.

PMID:
30935574
32.

ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.

Shaw AT, Solomon BJ, Besse B, Bauer TM, Lin CC, Soo RA, Riely GJ, Ou SI, Clancy JS, Li S, Abbattista A, Thurm H, Satouchi M, Camidge DR, Kao S, Chiari R, Gadgeel SM, Felip E, Martini JF.

J Clin Oncol. 2019 Jun 1;37(16):1370-1379. doi: 10.1200/JCO.18.02236. Epub 2019 Mar 20.

PMID:
30892989
33.

Clinical Management of Adverse Events Associated with Lorlatinib.

Bauer TM, Felip E, Solomon BJ, Thurm H, Peltz G, Chioda MD, Shaw AT.

Oncologist. 2019 Aug;24(8):1103-1110. doi: 10.1634/theoncologist.2018-0380. Epub 2019 Mar 19.

34.

Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study.

Leighl NB, Hellmann MD, Hui R, Carcereny E, Felip E, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, Patnaik A, Gubens M, Ramalingam SS, Lubiniecki GM, Zhang J, Piperdi B, Garon EB.

Lancet Respir Med. 2019 Apr;7(4):347-357. doi: 10.1016/S2213-2600(18)30500-9. Epub 2019 Mar 12.

PMID:
30876831
35.

Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).

Dziadziuszko R, Smit EF, Dafni U, Wolf J, Wasąg B, Biernat W, Finn SP, Kammler R, Tsourti Z, Rabaglio M, Ruepp B, Roschitzki-Voser H, Stahel RA, Felip E, Peters S.

J Thorac Oncol. 2019 Jun;14(6):1086-1094. doi: 10.1016/j.jtho.2019.02.017. Epub 2019 Feb 27.

PMID:
30825613
36.

Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol.

Levy B, Paz-Ares L, Bennouna J, Felip E, Abreu DR, Isla D, Barlesi F, Molinier O, Madelaine J, Audigier-Valette C, Kim SW, Kim HR, Ozguroglu M, Erman M, Badin FB, Mekhail TM, Scheff R, Chisamore MJ, Sadrolhefazi B, Riess JW.

Clin Lung Cancer. 2019 May;20(3):e407-e412. doi: 10.1016/j.cllc.2018.12.022. Epub 2019 Jan 4.

37.

Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors.

Nadal E, Massuti B, Dómine M, García-Campelo R, Cobo M, Felip E.

Cancer Immunol Immunother. 2019 Mar;68(3):341-352. doi: 10.1007/s00262-019-02310-2. Epub 2019 Feb 6. Review.

PMID:
30725206
38.

Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC.

Barlesi F, Garon EB, Kim DW, Felip E, Han JY, Kim JH, Ahn MJ, Fidler MJ, Gubens MA, de Castro G Jr, Surmont V, Li Q, Deitz AC, Lubiniecki GM, Herbst RS.

J Thorac Oncol. 2019 May;14(5):793-801. doi: 10.1016/j.jtho.2019.01.016. Epub 2019 Jan 31. Erratum in: J Thorac Oncol. 2019 Jul;14(7):1306.

PMID:
30711649
39.

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial.

Herbst RS, Baas P, Perez-Gracia JL, Felip E, Kim DW, Han JY, Molina JR, Kim JH, Dubos Arvis C, Ahn MJ, Majem M, Fidler MJ, Surmont V, de Castro G, Garrido M, Shentu Y, Emancipator K, Samkari A, Jensen EH, Lubiniecki GM, Garon EB.

Ann Oncol. 2019 Feb 1;30(2):281-289. doi: 10.1093/annonc/mdy545.

PMID:
30657853
40.

Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.

Levy BP, Giaccone G, Besse B, Felip E, Garassino MC, Domine Gomez M, Garrido P, Piperdi B, Ponce-Aix S, Menezes D, MacBeth KJ, Risueño A, Slepetis R, Wu X, Fandi A, Paz-Ares L.

Eur J Cancer. 2019 Feb;108:120-128. doi: 10.1016/j.ejca.2018.11.028. Epub 2019 Jan 14.

PMID:
30654297
41.

Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).

Peters S, Dafni U, Boyer M, De Ruysscher D, Faivre-Finn C, Felip E, Garrido P, Girard N, Guckenberger M, Haanen J, Le Pechoux C, Mornex F, Ozsahin M, Paz-Ares L, Planchard D, Raben D, Ramalingam S, Reck M, Smit E, Stahel R, Stenzinger A, Swanton C, Vallone S, Garassino MC.

Ann Oncol. 2019 Feb 1;30(2):161-165. doi: 10.1093/annonc/mdy553. No abstract available.

PMID:
30624547
42.

Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.

Zugazagoitia J, Ramos I, Trigo JM, Palka M, Gómez-Rueda A, Jantus-Lewintre E, Camps C, Isla D, Iranzo P, Ponce-Aix S, García-Campelo R, Provencio M, Franco F, Bernabé R, Juan-Vidal O, Felip E, de Castro J, Sanchez-Torres JM, Faul I, Lanman RB, Garrido P, Paz-Ares L.

Ann Oncol. 2019 Feb 1;30(2):290-296. doi: 10.1093/annonc/mdy512.

PMID:
30535340
43.

5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging.

Martínez-Terroba E, Behrens C, Agorreta J, Monsó E, Millares L, Felip E, Rosell R, Ramirez JL, Remirez A, Torre W, Gil-Bazo I, Idoate MA, de-Torres JP, Pio R, Wistuba II, Pajares MJ, Montuenga LM.

Thorax. 2019 Apr;74(4):371-379. doi: 10.1136/thoraxjnl-2018-212194. Epub 2018 Nov 24.

PMID:
30472670
44.

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.

Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, Chiari R, Bearz A, Lin CC, Gadgeel SM, Riely GJ, Tan EH, Seto T, James LP, Clancy JS, Abbattista A, Martini JF, Chen J, Peltz G, Thurm H, Ou SI, Shaw AT.

Lancet Oncol. 2018 Dec;19(12):1654-1667. doi: 10.1016/S1470-2045(18)30649-1. Epub 2018 Nov 6. Erratum in: Lancet Oncol. 2019 Jan;20(1):e10.

PMID:
30413378
45.

Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors.

Fassunke J, Müller F, Keul M, Michels S, Dammert MA, Schmitt A, Plenker D, Lategahn J, Heydt C, Brägelmann J, Tumbrink HL, Alber Y, Klein S, Heimsoeth A, Dahmen I, Fischer RN, Scheffler M, Ihle MA, Priesner V, Scheel AH, Wagener S, Kron A, Frank K, Garbert K, Persigehl T, Püsken M, Haneder S, Schaaf B, Rodermann E, Engel-Riedel W, Felip E, Smit EF, Merkelbach-Bruse S, Reinhardt HC, Kast SM, Wolf J, Rauh D, Büttner R, Sos ML.

Nat Commun. 2018 Nov 7;9(1):4655. doi: 10.1038/s41467-018-07078-0.

46.

COX-2 inhibitors in NSCLC: never-ending story or misplaced?

Martinez-Marti A, Navarro A, Felip E.

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S191-S194. doi: 10.21037/tlcr.2018.04.17. No abstract available.

47.

Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.

Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, Hochmair MJ, Li JY, Chang GC, Lee KH, Gridelli C, Delmonte A, Garcia Campelo R, Kim DW, Bearz A, Griesinger F, Morabito A, Felip E, Califano R, Ghosh S, Spira A, Gettinger SN, Tiseo M, Gupta N, Haney J, Kerstein D, Popat S.

N Engl J Med. 2018 Nov 22;379(21):2027-2039. doi: 10.1056/NEJMoa1810171. Epub 2018 Sep 25.

48.

Lung cancer in Spanish women: The WORLD07 project.

Garrido P, Viñolas N, Isla D, Provencio M, Majem M, Artal A, Carcereny E, Garcia Campelo R, Lianes P, De La Peñas R, Felip E.

Eur J Cancer Care (Engl). 2019 Jan;28(1):e12941. doi: 10.1111/ecc.12941. Epub 2018 Oct 2.

PMID:
30277293
49.

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer.

Blumenthal GM, Bunn PA Jr, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, Drezner NL, Doebele RC, Blakely CM, Eberhardt WEE, Felip E, Gianni L, Keller SP, Leavey PJ, Malik S, Pignatti F, Prowell TM, Redman MW, Rizvi NA, Rosell R, Rusch V, de Ruysscher D, Schwartz LH, Sridhara R, Stahel RA, Swisher S, Taube JM, Travis WD, Keegan P, Wiens JR, Wistuba II, Wynes MW, Hirsch FR, Kris MG.

J Thorac Oncol. 2018 Dec;13(12):1818-1831. doi: 10.1016/j.jtho.2018.09.017. Epub 2018 Sep 27. Review.

50.

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.

Wu YL, Zhang L, Kim DW, Liu X, Lee DH, Yang JC, Ahn MJ, Vansteenkiste JF, Su WC, Felip E, Chia V, Glaser S, Pultar P, Zhao S, Peng B, Akimov M, Tan DSW.

J Clin Oncol. 2018 Nov 1;36(31):3101-3109. doi: 10.1200/JCO.2018.77.7326. Epub 2018 Aug 29. Erratum in: J Clin Oncol. 2019 Jan 20;37(3):261.

PMID:
30156984

Supplemental Content

Support Center